Recently-released US FDA briefing documents reveal an ambiguous response to data for a candidate developed by Sarepta Therapeutics (Nasdaq: SRPT).
A scientific panel of the US Food and Drug Administration is set to review the evidence for investigational Duchenne muscular dystrophy (DMD) therapy SRP-9001 (delandistrogene moxeparvovec) on Friday.
The agency’s Cellular, Tissue, and Gene Therapies Advisory Committee will consider the use of a particular surrogate endpoint as a predictor of clinical benefit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze